Prediction of outcome in dilated cardiomyopathy

RIENZI A DIAZ, AUSTINE OBASOHAN, CELIA M OAKLEY

From the Department of Medicine (Clinical Cardiology), Royal Postgraduate Medical School, Hammersmith Hospital, London

SUMMARY One hundred and sixty nine patients (mean age 39.1 years) with documented dilated cardiomyopathy were studied for a mean of 5.5 years. One hundred and four patients died during this period. The average (SD) interval from the onset of symptoms to death was 4.1 (3.7) years. One year and five year mortality rates were 27.8% and 57.4% respectively. Most of the deaths occurred within two years of diagnosis. The only difference between survivors and those who died was in the severity of left ventricular dysfunction at the time of referral. Significant differences between survivors and non-survivors were found for left ventricular end diastolic pressure (17.3 versus 23.4 mmHg), left ventricular end systolic volume (87.4 versus 128.9 ml/m^2), left ventricular end diastolic volume (130.7 versus 173.2 ml/m^2), and ejection fraction (32.8 versus 25.4%). The duration of previous symptoms, preceding virus infection, positive family history, recent pregnancy, or heavy alcohol intake did not seem to influence prognosis. Nor did treatment, which was similar in both groups with a quarter of the patients receiving vasodilators.

Patients with dilated cardiomyopathy have a high mortality irrespective of treatment. The only identifiable prognostic indicator was the severity of left ventricular impairment at referral.

Dilated cardiomyopathy is a heart muscle disease of unknown cause in which one or both ventricles are dilated and poorly contracting. Various clinical, radiological, angiographic, haemodynamic, and histopathological variables have been suggested as predictors of outcome in dilated cardiomyopathy, but there is no uniform agreement about their usefulness.

One year mortality in this condition may vary from 31% to 35% and five year mortality has been reported to be around 50%. This poor prognosis seems not to have been modified during the past two decades, despite the introduction of new diuretics and the use of vasodilators and anticoagulants during this period.

To strengthen understanding of the clinical course of this disorder we report experience at Hammersmith Hospital in the diagnosis, treatment, and follow up of these patients. To our knowledge this is the largest series of patients with well documented dilated cardiomyopathy so far reported and the observations are relevant to the selection of patients for cardiac transplantation and the timing of the operation.

Patients and methods

We retrospectively analysed data on 209 consecutive patients with dilated cardiomyopathy who were first seen in the Clinical Cardiology Unit (Department of Medicine) at Hammersmith Hospital from March 1962 to March 1982. Only 169 patients were included in the study. Eighteen patients were excluded because data were incomplete and twenty two were excluded because they had predominant or exclusive dilatation of the right ventricle. Most patients were referred for the evaluation of cardiac failure. All patients were followed up in the outpatient department. The follow up period was defined as the interval from the date of first admission to Hammersmith Hospital until either death or 31 March 1983. The interval from the onset of symptoms to the first admission was also analysed. There were 131 men and 38 women. One hundred and thirty eight patients were European, 17 were black, and 14 were Asian.

Dilated cardiomyopathy was identified as a heart muscle disease of unknown cause with dilatation of the left or right heart or both, so the diagnosis...
was made by exclusion of other causes of cardiac failure. Exclusion criteria included: heart muscle disease of known origin (for example amyloid, sarcoid, haemochromatosis), clinical or angiographic coronary heart disease or both (patients with obstruction of \( \geq 50\% \) of one or more major coronary artery branches or who had considerable irregularity of one or more vessels were excluded even if it was thought that the left ventricular failure could not be attributed to the coronary disease shown on angiography), systemic hypertension, and hypertrophic cardiomyopathy. The diagnosis required a left ventricular ejection fraction of \(<45\% \) and usually included also: (a) a history of dyspnoea on exertion or at rest; (b) physical signs of left or right heart failure or both; (c) cardiomegaly on chest x ray; (d) one or more of the following electrocardiographic abnormalities—atrial fibrillation or atrial flutter, conduction system disturbances, and evidence of a left ventricular disorder usually with high voltage in the chest leads and repolarisation abnormalities; (e) left ventricular end diastolic pressure >15 mm Hg.

The symptomatic state was classified according to the New York Heart Association classification. Death was defined as sudden when it was unexpected and occurred within 24 hours of the onset of new symptoms. Complex ventricular arrhythmia was defined as the presence of multiformal or repetitive ventricular extrasystoles (couplets or bursts of ventricular tachycardia) or both.

To evaluate possible risk factors we analysed alcohol intake, recent pregnancy, family history and febrile illness heralding the onset of symptoms, and positive anti-viral titres.

### MEASUREMENTS

All patients had a baseline 12 lead electrocardiogram and chest x ray. R waves in the left precordial lead V5 over 20 mV were considered as high voltage and under 5 mV as low voltage. Ambulant electrocardiogram monitoring was carried out in all patients seen after 1980—57% of the total series. Blood samples were also taken to measure serum iron, antinuclear factor, thyroid function, rheumatoid factor, and virus antibody titres.

### HAEMODYNAMIC AND ANGIOGRAPHIC STUDIES

All patients underwent cardiac catheterisation by the percutaneous approach through the femoral or brachial artery. Left and right heart pressures were recorded with an Electronics for Medicine DR8 recorder. Fluid filled lines and P23D Statham transducers were used. The mid chest was used as a reference point for the calibration of zero.

Left ventricular volumes were determined by Grant et al's method\(^\text{10}\) from the biplane anteroposterior and lateral projections filmed at 30 frames/s after the injection of contrast material into the left ventricle. The ejection fraction (EF) was calculated by the formula: \( EF = \frac{(LVEDV - LVESV)/LVEDV}{LVEDV} \), where \( LVEDV = \text{left ventricular end systolic volume} \) and \( LVESV = \text{left ventricular end diastolic volume} \). Volumes are given as millilitres per square metre of body surface area \((\text{ml/m}^2)\). Ninety seven \((57\%)\) of the patients underwent coronary angiography. This includes all patients studied since 1980 irrespective of age. Those who did not have angiography had no clinical, electrocardiographic, or ventriculographic features of coronary heart disease and none who came to necropsy had clinically significant coronary atheroma. Thirty two \((18\%\)\) patients underwent percutaneous right ventricular endomyocardial biopsy. Biopsy was used to identify myocarditis and the specific heart muscle diseases.\(^\text{11}\) All endomyocardial biopsy specimens in the current series showed nonspecific morphological abnormalities and there was no evidence of active or past myocarditis. Since March 1983 we have performed myocardial biopsies on 39 more patients with clinically similar dilated cardiomyopathy, 21 of whom were reported as showing features of active past or healing myocarditis on biopsy.

Echocardiographic and radionuclide measurements were not included in this analysis because they only became available after the series was started.

\[ \text{Fig 1} \quad \text{10 year survival curve of 169 patients with dilated cardiomyopathy. Numbers in parentheses are patients alive at the beginning of interval. Numbers at years 6, 7, 8, and 9 were omitted because of the small amount of attrition between 5 and 10 years.} \]
Prediction of outcome in dilated cardiomyopathy

TREATMENT
All patients were taking diuretics. Digitalis preparations were not used routinely in patients in sinus rhythm. Anticoagulant drugs are normally prescribed when dilated cardiomyopathy is diagnosed, irrespective of the cardiac rhythm. One quarter of the patients received vasodilator drugs.

STATISTICAL ANALYSIS
The data were stored in a computer and analysed by the statistical package, Minitab. The probability of survival from the time of first evaluation at Hammersmith Hospital was analysed by the life table method. The t test and χ² test were used to analyse significance of univariate prognostic factors. Linear regression analysis was carried out to test the relation between clinical or haemodynamic variables and the duration of survival in those who died. Results were considered to be statistically significant when p < 0.05.

Results
One hundred and sixty nine patients with documented dilated cardiomyopathy were studied. The mean (SD) age at the onset of symptoms was 39.1 (14.1) years. The interval from the onset of symptoms to first evaluation at Hammersmith Hospital was 1.8 (2.8) years. The average duration from the onset of symptoms to death was 4.1 (3.7) years. The mean follow up period was 5.5 (4.2) years. Patients who survived five years were unlikely to die thereafter (fig 1).

CLINICAL CHARACTERISTICS
Table 1 summarises the clinical symptoms and physical signs found on the first admission to Hammersmith Hospital. The commonest symptom was dyspnoea either on exertion or at rest (85.8%) followed by palpitation and oedema. Chest pain was not uncommon and it was present in 35 patients (20.7%), all of whom underwent coronary angiography which excluded clinically significant coronary artery disease as defined earlier. A mitral regurgitant murmur was present in 37.9% of the patients. Pulmonary or systemic embolism had occurred in 10.6% and 8.3% respectively before referral to Hammersmith. Atrial fibrillation was present in only 23.7% of those patients who had had embolic events. Asymptomatic cardiomegaly was the first manifestation of illness in eight (4.7%) patients.

All patients had radiographic evidence of cardiomegaly and the average cardiothoracic index was 58.8 (6.8%).

Table 2 shows electrocardiographic features. Atrial fibrillation and ventricular extrasystoles were the commonest arrhythmias present in this series. Complex ventricular arrhythmias were present in 14.8% of the patients. Complete left bundle branch block was the commonest conduction system defect (20.7%). Right bundle branch block was rarely present (4.1%). High voltages (>20 mV) in the left precordial lead V5 occurred in 34.4% of the cases while low voltages (<5 mV) were occasionally seen (3.2%). Arrhythmias were documented by routine Holter recording in 97 patients investigated after 1980. Before that date, complex ventricular arrhythmias or ventricular tachycardia were only found by chance recording or when they caused symptoms.

HAEMODYNAMIC FEATURES
Table 3 shows the baseline haemodynamic findings. The left ventricular end diastolic pressure was raised (20.8 (9.8) mm Hg) and the ejection fraction was reduced (29.2 (12.7)%). Both the left ventricular end systolic volume (104.7 (57.1) ml/m²) and the end diastolic volume (148.4 (64.2) ml/m²) were increased. The mean stroke volume (42.1 (22.5) ml/m²) was at the lower limit of normal but there was wide variation.

The left ventricular angiograms showed a markedly dilated and poorly contracting left ventricle in all patients, with mitral regurgitation ranging from 0 to moderate (grade 2 out of 4).

During the period of analysis 104 of the 169 patients died. Nearly all deaths were cardiac in origin.
Table 3  Haemodynamic and angiographic variables of patients with dilated cardiomyopathy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
<th>Normal value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEDP (mm Hg)</td>
<td>20.8 (9.8)</td>
<td>&lt; 12</td>
</tr>
<tr>
<td>LVESE (ml/m²)</td>
<td>10.4 (57)</td>
<td>21-34</td>
</tr>
<tr>
<td>LVEDV (ml/m²)</td>
<td>148 (64.2)</td>
<td>64-96</td>
</tr>
<tr>
<td>SV (ml/m²)</td>
<td>42.1 (22.5)</td>
<td>43-62</td>
</tr>
<tr>
<td>EF (%o)</td>
<td>29.2 (12.7)</td>
<td>63-72</td>
</tr>
</tbody>
</table>

LVEDP, left ventricular end diastolic pressure; LVESE, left ventricular end systolic volume; LVEDV, left ventricular end diastolic volume; SV, stroke volume; EF, ejection fraction.

and sudden death occurred in 8.6% of the cases. Figure 1 shows the cumulative survival rates. The survival curve shows a one year survival rate of 72.2%. Five year survival was 42.6%. Most of the deaths occurred during the first two years of follow up (41.4%).

In order to determine whether there were differences between patients who were still alive (survivors) and those who were dead (non-survivors) at the end of the analysis period we compared the baseline clinical, serological (virus), electrocardiographic, radiographic, and haemodynamic variables of both groups. No significance differences were found either in the clinical or in the electrocardiographic variables between survivors and non-survivors nor any difference in the cardiothoracic ratio (table 4). The only significant differences between survivors and non-survivors were with the haemodynamic and angiographic variables shown in table 5. Those who died had higher left ventricular end diastolic pressure than did the survivors (23.4 versus 17.3 mm Hg; p < 0.001). They also had lower ejection fractions (25.4 versus 32.8%; p < 0.005) and larger left ventricular end systolic volumes (128.9 versus 87.4 ml/m²; p < 0.01) and left ventricular end diastolic volumes (173.2 versus 130.7 ml/m²; p < 0.01) than did the survivors. The stroke volume was similar in both groups (43.2 versus 40.6 ml/m²; p NS).

Linear regression analysis between the clinical, electrocardiographic, radiographic, haemodynamic,

Table 4  Comparison of clinical, electrocardiographic, and radiological variables (mean (SD)) in survivors and those who died

<table>
<thead>
<tr>
<th>Variable</th>
<th>Survivors</th>
<th>Died</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (No)</td>
<td>67</td>
<td>102</td>
<td>NS</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>42.4 (13.1)</td>
<td>37.0 (14.4)</td>
<td>NS</td>
</tr>
<tr>
<td>LA enlargement (mm)</td>
<td>55.7 (7.2)</td>
<td>57.9 (6.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Atrial fibrillation (No)</td>
<td>28/67</td>
<td>48/102</td>
<td>NS</td>
</tr>
<tr>
<td>VPB complex (No)</td>
<td>16/67</td>
<td>18/102</td>
<td>NS</td>
</tr>
<tr>
<td>LBBB (No)</td>
<td>14/67</td>
<td>22/102</td>
<td>NS</td>
</tr>
<tr>
<td>Embolism (No)</td>
<td>10/67</td>
<td>21/102</td>
<td>NS</td>
</tr>
</tbody>
</table>

See table 2 for abbreviations.

Table 5  Comparison of haemodynamic and angiographic variables (Mean (SD)) in survivors and those who died

<table>
<thead>
<tr>
<th>Variable</th>
<th>Survived</th>
<th>Died</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEDP (mm Hg)</td>
<td>17.3 (7.8)</td>
<td>23.4 (9.3)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>LVESE (ml/m²)</td>
<td>87.4 (58.6)</td>
<td>128.9 (45.8)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>LVEDV (ml/m²)</td>
<td>130.7 (66.7)</td>
<td>173.2 (52.9)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>EF (%o)</td>
<td>32.8 (11.6)</td>
<td>25.4 (12.8)</td>
<td>&lt; 0.005</td>
</tr>
</tbody>
</table>

See table 3 for abbreviations.
Prediction of outcome in dilated cardiomyopathy

Table 6 Duration of survival and number of deaths according to first manifestation of illness in 169 patients with dilated cardiomyopathy

<table>
<thead>
<tr>
<th>Heart failure</th>
<th>Other</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths (No)</td>
<td>88/145</td>
<td>14/24</td>
</tr>
<tr>
<td>Survival (yr)</td>
<td>2·2 (2·4)</td>
<td>2·6 (3·8)</td>
</tr>
</tbody>
</table>

Table 7 Symptomatic state at the last follow up

<table>
<thead>
<tr>
<th>NYHA</th>
<th>Survivors</th>
<th>Non-survivors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I or II</td>
<td>85·2%</td>
<td>30·7%</td>
</tr>
<tr>
<td>Class II or IV</td>
<td>14·2%</td>
<td>69·3%</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association classification.

Table 8 Vasodilator treatment

<table>
<thead>
<tr>
<th>Variable</th>
<th>No vasodilators</th>
<th>Vasodilators</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEDP (mm Hg)</td>
<td>19·5 (8·9)</td>
<td>22·5 (9·6)</td>
<td>NS</td>
</tr>
<tr>
<td>LVEDV (ml/m²)</td>
<td>135·8 (33·0)</td>
<td>167·8 (84·8)</td>
<td>NS</td>
</tr>
<tr>
<td>LVESV (ml/m²)</td>
<td>92·1 (41·6)</td>
<td>126·2 (82·0)</td>
<td>NS</td>
</tr>
<tr>
<td>EF (%)</td>
<td>30·2 (13·2)</td>
<td>26·9 (12·3)</td>
<td>NS</td>
</tr>
</tbody>
</table>

See table 3 for abbreviations.

Discussion

Dilated cardiomyopathy is a heart muscle disease of unknown cause. All four cardiac chambers may be dilated or only the left ventricle, and rarely only the right ventricle is dilated. Patients with only right ventricular dilatation were not included in this study. The commonest mode of presentation is heart failure. Both shortness of breath and ventricular gallop were present in 85·8% of our patients. The clinical course is unpredictable. Most of these patients worsened quickly and died within the first two years after referral and within four years of the onset of symptoms, irrespective of the treatment used. Because we are a tertiary referral centre these figures may seem to be worse than they really are. Some of our patients referred after one to two years of treatment were undoubtedly only referred because they were deteriorating. Patients who were “doing all right”, overt alcoholics, or the elderly may not have been referred. Despite this probable selection, a trend towards rapid mortality has been reported in other published series as well as ours and the prognosis in this heart condition is one of the poorest. In the current series we observed a one year mortality of 27·8% and a five year mortality of over 50%. Most of our patients died within two years of the first evaluation at Hammersmith Hospital (fig 1). Conversely, patients who survived longer than this showed little tendency to die later. These were the patients who came to us despite not being on an obviously down-hill course. Their duration of symptoms before referral was similar to that in the patients who died. It is possible, indeed probable, that we are dealing with more than one disease process, but it is important to realise that a few patients with dilated cardiomyopathy can do well, with a good quality of life, and stable condition over many years even if they do not actually improve or “get better”.

In several reports some clinical and haemodynamic variables have been advocated as useful predictors of the clinical course. Years ago Hatle et al reported a poor outcome in those patients with both low voltages and evidence of left atrial enlargement on the electrocardiogram. On the other hand, atrial fibrillation and left ventricular hypertrophy are factors considered to be associated with longevity. Though the survivors in the current series showed a trend towards higher voltage on the electrocardiogram than those who died, the difference was not significant nor was the difference in the presence of atrial fibrillation. A favourable course has also been reported in patients who developed systemic hypertension after successful treatment for heart failure. Pati...
electrocardiogram monitoring.\textsuperscript{22,23} Huang \textit{et al} reported that ventricular tachycardia was not predictive in their series.\textsuperscript{22} Von Olshausen \textit{et al} also concluded that patients at higher risk are more reliably identified by their severely impaired left ventricular function than by ventricular arrhythmias.\textsuperscript{23,24} This fits in with our observation that death was rarely unexpected and rarely occurred in patients with better preserved left ventricular function. Ventricular arrhythmias were most common in those with the poorest ventricular function. In our series the only significant differences between survivors and those who died applied to haemodynamic variables. Those who died had higher left ventricular end diastolic pressure, larger end systolic and end diastolic volumes, and lower ejection fractions than the survivors; and left ventricular function overrode all other features in the prediction of prognosis (table 5). This accords with previous reports.\textsuperscript{7,17,24} Only end diastolic pressure showed significant inverse correlation with length of survival. The higher the end diastolic pressure, the shorter the survival period tended to be (fig 2). It is interesting and important that stroke volume was not predictive. The resting cardiac output was often normal, although it failed to rise normally on effort. This was associated with a less than normal rise in rate but the poor exercise response can only be explained by a fall in stroke volume on exercise even though ventricular filling is completed rapidly. This indicates a reduction in filling, perhaps caused by a poorer systolic contraction on exercise or a decrease in compliance. Only after a very advanced stage does the resting cardiac output fail and this is shown by Fuster's bad prognostic factors one of which was a cardiac index of $< 3.0$, which exceeds the lower limit of normal of most laboratories.

We did not find any correlation between prognosis and febrile illness heralding the onset of symptoms, pregnancy, or excessive alcohol intake. High neutralisation titres to Coxsackie B virus were similar in survivors and those who died but in a previous report from our institution an increased frequency of high titres had been found in patients with a short history of symptoms.\textsuperscript{25} Pulmonary and systemic embolism occurred in 10\%-1\% and 8\%-3\% respectively and all episodes occurred before referral to us and before the introduction of anticoagulants. These episodes had occurred irrespective of the cardiac rhythm. In fact, atrial fibrillation was only present in 23\%-7\% of those patients who developed embolism. All patients with dilated cardiomyopathy seen at Hammersmith Hospital were given anticoagulants on diagnosis and no further embolism occurred.

All patients were on diuretics and all of those in atrial fibrillation were taking digoxin. One quarter of them were also taking vasodilator drugs. The efficacy of vasodilators in improving the haemodynamic state in these patients has already been proved\textsuperscript{26,27} but the improvement in measured exercise capacity is disappointing. Since vasodilators tended to be given to patients with worse left ventricular function (table 8) it was not possible to evaluate statistically the effect of these drugs on prognosis but there was certainly no obvious benefit in patients with advanced disease.

Despite two decades of hard investigation of dilated cardiomyopathy, the underlying cause or causes are still unknown and no treatment is yet available to reverse pathogenesis. Only an understanding of the underlying causes will make specific treatment possible. Improvement in the prognosis of these patients will only come when this knowledge is coupled with earlier recognition. We were unable to confirm from our data the suggestion that virus myocarditis had preceded or initiated dilated cardiomyopathy but we are perplexed by the great increase in biopsy diagnosis of myocarditis since 1982.

This is the largest series of patients with dilated cardiomyopathy so far reported. Its analysis confirmed that the disorder has a high mortality irrespective of the type of treatment, and the severity of left ventricular functional impairment (at referral) appears to be the main determinant of reduced survival, possibly because by the time symptoms develop or become at all limiting, dilatation may already have reached the point at which further deterioration is inevitable. Our observations are of importance in deciding the timing of cardiac transplantation. Some patients continue to do well and are stable for many years but patients with ejection fractions below 25\% and deteriorating symptoms are unlikely to survive more than two years and may die at any time.

References

2 Goodwin JF, Oakley CM. The cardiomyopathies. \textit{Br Heart J} 1972;34:545-52.
Prediction of outcome in dilated cardiomyopathy


Prediction of outcome in dilated cardiomyopathy.

R A Diaz, A Obasohan and C M Oakley

*Br Heart J* 1987 58: 393-399
doi: 10.1136/hrt.58.4.393

Updated information and services can be found at:
http://heart.bmj.com/content/58/4/393

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/